Who We Are

Who We Are

MolecularMatch is a Clinical Decision Support company founded on the vision of using genetics, and outcomes from previously-treated patients to provide the best personalized treatment for current patients. Our patented technology continuously aggregates all oncology-related targeted drugs, immunotherapies, clinical trials, literature and publications in the cloud, to provide real-time personalized medicine on a global basis.

Meet the Team

ERIC PULASKI
ERIC PULASKI
President

Mr. Pulaski has over 30 years’ experience in leadership of entrepreneurial to professional management including most aspects of start-up, hyper growth, downsizing, and merger and acquisition transactions including exit via corporate sale. Eric was the chairman and CEO of BindView Corp., which he founded in 1990. Under his management, the company evolved from a three-man software development firm to a public company with over 850 employees on four continents, leading to the ultimate sale of the company to Symantec Corporation in 2006. Eric was most recently founder and CEO of SmartVault, a cloud-based document management company that delivers solutions for businesses to store and share files over the internet. SmartVault has over 500,000 users, primarily in the accounting, tax and financial services vertical markets, where SmartVault is a leading Client Portal solution to help firms manage their paperless workflow and stay in compliance while collaborating with their clients. SmartVault was sold in 2016 to Reckon Limited, an Australian public company. Eric holds a Bachelors of Arts degree in Humanities from the University of Texas at Austin, and provides philanthropic support to the arts, health care, and educational organizations. He also serves on the board of directors for Holocaust Museum Houston.

JAMES W. WELSH, MD
JAMES W. WELSH, MD
Founder

James W. Welsh, MD, specializes in the treatment of thoracic cancers at the M.D. Anderson Cancer Center. His oncology career began at Genentech Inc., working on the first targeted therapies. He later attended Dartmouth Medical School, where his laboratory work was developing AKT inhibitors to radiosensitize tumors. He completed a residency in radiation oncology at the University of Arizona, where he also ran a laboratory focused on radiosensitizers, which lead to a novel c-Met inhibitor MP470. He joined the clinical faculty at M.D. Anderson in 2008. His pursuits extend from the laboratory to the clinic, with a focus on translational research, developing novel personalized therapeutics and immunotherapies to combine with radiation.

NICK TACKES
NICK TACKES
Founder, Chief Technology Officer

Nick has been architecting and implementing enterprise applications for over 20 years. Grounded in collaborative development and user-centered design, Nick applies his experience in full-stack architecture. He co-developed GluJs, an open source UI framework for building enterprise-ready web and mobile applications. He holds a Bachelor’s of Science degree in Electrical Engineering from Bradley University.

RYAN DUREN, PHD
RYAN DUREN, PHD
Senior Director, Scientific Development

Ryan has worked in both academic and pharmaceutical research and oversees the integration of molecular and clinical knowledge into MolecularMatch software applications. His experience includes transcriptomic profiling, epigenetics, and mouse models of disease. He received his PhD in cellular and molecular biology from Baylor College of Medicine where he also completed postdoctoral training.

DON CORLEY
DON CORLEY
Vice President, Business Development

Don has been in healthcare for nearly 30 years and oversees new business development for MolecularMatch.  He boasts a comprehensive understanding of genomics, bioinformatics and integrated healthcare IT systems.  Formerly at Baylor College of Medicine’s Genetics Lab, he was Director of Strategic Partnerships overseeing both national and international clients.

Advisors

JACK GILL
JACK GILL
Advisor and Board Member

Jack M. Gill, PhD holds the position of Professor in the Practice of Entrepreneurship at Rice University and the Texas Medical Center.  He was formerly a member of the Harvard Medical School faculty, a senior advisor to the Harvard-MIT CIMIT program, a professor at Harvard Medical School and MIT (2000-2010), and previously an adjunct professor at Stanford.  Dr. Gill is a founder and Managing Member (retired) of Vanguard Ventures, a venture capital firm specializing in high technology start-ups, with offices in Palo Alto, California and Houston, Texas. Vanguard managed over $500 million capital and was the lead investor in numerous highly successful companies.  Prior to co-founding Vanguard in 1981, Dr. Gill was Executive V.P. and Group Manager of the Scientific Divisions of Spectra Physics, Inc., a NYSE listed company.  In 1970, Dr. Gill founded Autolab, which pioneered the application of microprocessor-based instruments and computers for chromatography and laboratory applications. Autolab was merged into Spectra Physics in 1972.

Dr. Gill is a native of Lufkin, Texas. He earned a chemistry and engineering degree from Lamar University in 1958 and a Ph.D. in Organic Chemistry from Indiana University in 1963.  He received Distinguished Alumnus Awards from Lufkin High School, Lamar University and Indiana University.  Jack was named a 1999 winner of the Horatio Alger Award for Distinguished Americans.  In May 2001, he received an Honorary Doctorate of Science from Indiana University. In addition, he has received numerous Entrepreneur Awards and Teaching Awards throughout the USA.  Dr. Gill is a Trustee (retired) of Indiana University and a Board member (retired) of the Texas Emerging Technology Fund. He is a Director of the UT MD Anderson Cancer Center, the Horatio Alger Association, Project HOPE and the Presidents Circle of the National Academies of Science, Engineering, and Medicine.

KEVIN KRENITSKY, MD
KEVIN KRENITSKY, MD
Advisor and Board Member

Dr. Krenitsky brings more than 15 years of experience leading and managing global diagnostic and biotechnology operations.  Through December 2014, Dr. Krenitsky was Chief Commercial Officer & SVP of International Strategy and previously Chief Operating officer at Foundation Medicine. Prior to that, he served as President of Enzo Clnical Labs, where he instituted a comprehensive strategic and operational plan that led to the introduction and launch of numerous FDA-approved esoteric tests.  Dr. Krenitsky has also served as Chief Executive Officer at both a global biotechnology company and a Clinical Diagnostic Lab. Dr. Krenitsky received his B.S. in Business Management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel Medical College) in Philadelphia.  He is a former member of the Board of Directors of the New York State Clinical Lab Assocation and of BioServe Biotechnologies, and currently serves on the Board of Directors at Lumicell.

NANCY T. CHANG, PHD
NANCY T. CHANG, PHD
Advisor

Dr. Chang currently serves as the CEO/President of Apex Enterprises, Inc., an investment management company focused on investments in healthcare, education and socially responsible ventures. In addition to investing, Apex also participates in active operations of companies including STEAMtrax, LLC., where Dr. Chang is a member of the Board of Managers. Prior to that Dr. Nancy was the Co-Founder, President, Chief Executive Officer and Chairman of Tanox (1986-2006). Tanox focused its effort on the development of therapeutics to address major unmet medical needs in the areas of asthma, allergy, inflammation, aged macular degeneration and other diseases affecting the human immune system. Dr. Chang’s pharmaceutical development experience stemmed from her tenure at the Roche Institute of Molecular Biology from 1979-1980. Dr. Chang graduated from National Tsing Hua University in Taiwan and received her Ph. D. from Harvard University, the Division of Medical Sciences at Harvard Medical School in 1979.

In her over 30 year tenure in the biotechnology industry, she has developed and commercialized a number of highly successful diagnostic and therapeutic products. Even today, there are breakthrough drugs are coming to the market due to Dr. Chang’s work. Dr. Chang has served on the boards of a number of companies, including Charles River Laboratory International, Inc., Eddingpharm (Cayman) Inc., Crown Bioscience Inc., Applied Optoelectronics Inc., SciClone Pharmaceuticals Inc. and STEAMtrax, LLC. and many other private companies. In addition, Dr. Chang was a member of the board of directors at BIO (the Biotech Industry Organization in the U.S.) and BioHouston (the biotech industry organization in Houston, Texas) and recently Dr. Chang was elected to be on the board of Asia Society in Texas. Dr. Chang was also a Director at the Federal Reserve Bank in Dallas, Houston Branch from 2005 to 2009 and a Director for Project Hope.

SCOTT KOPETZ, MD, PHD
SCOTT KOPETZ, MD, PHD
Advisor

Dr. Scott Kopetz graduated Summa Cum Laude from Vanderbilt University with a bachelor’s degree in Biomedical Engineering/Electrical and received his medical degree from Johns Hopkins School of Medicine. He obtained his residency training in Internal Medicine at Duke University Medical Center, followed by a medical oncology fellowship at M. D. Anderson Cancer Center. Dr. Kopetz joined M. D. Anderson Cancer Center in 2006 as an Assistant Professor of Medicine in the Department of Gastrointestinal Medical Oncology. He subsequently completed a Ph.D. at M.D. Anderson in cancer biology with thesis focus on mechanisms of chemotherapy resistance in colorectal cancer.

Dr. Kopetz is board-certified in Internal Medicine and in Medical Oncology. He has authored over 100 peer-reviewed articles in respected scientific journals such as Journal of Clinical Oncology, Lancet, Cancer Research, Cancer, Clinical Cancer Research, and JAMA, and is a senior editor for Clinical Cancer Research, and editorial board member on Journal of Clinical Oncology and JNCI. He is vice-chair for colon cancer research in the NSABP/RTOG cooperative group, and member of the NIH Gastrointestinal Oncology Steering Committee. In addition, he was a recipient of peer-reviewed grants from American Society of Clinical Oncology and the National Institute of Health, among others. He is the principal investigator several phase I and II clinical trials, including of Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) study, a novel biomarker enrichment program for colorectal cancer. His research interests include the biology of the refractory colorectal cancer and the development of novel therapeutics for molecularly distinct subsets of colorectal cancer patients.

DAVID S. HONG, MD
DAVID S. HONG, MD
Advisor

Dr. David S. Hong is an Associate Professor and Deputy Chair in the Department of Investigational Cancer Therapeutics (Phase I Program) at The University of Texas MD Anderson Cancer Center. The approach of the department is unique with an emphasis on molecular characterization of each patient’s tumor and personalized therapy in the Phase I setting. Throughout his career, Dr. Hong has developed an interest in studying the efficacy of novel drug combinations in patients with solid tumors. As a faculty member in the Department of Investigational Cancer Therapeutics he has an extensive track record of leading successful studies that involve a strong correlative component and collaborating with other investigators both basic and clinical within MD Anderson and outside institutions. Currently, he is the Principal Investigator on twenty research protocols that involve a wide range of sponsors including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. Dr. Hong has been an author or co-author on over 150 publications. Recently his research endeavors have focused on developing personalized therapies for patients whose tumors bear specific genetic mutations/amplifications. At this time, all patients presented to the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center are being screened for mutational status through the MD Anderson Department of Pathology using CLIA certified testing. Dr. Hong has demonstrated the ability to successfully place patients on clinical trials, manage toxicities and oversee the correlative studies associated with various phase I research projects.

EDWARD S. KIM, MD
EDWARD S. KIM, MD
Advisor

Dr. Kim is Chairman at the Levine Cancer Institute within the Carolinas HealthCare System. His previous experience includes tenure as an Associate Professor at MD Anderson Cancer Center. He specializes in Lung Cancer, Head and Neck Cancer, and Solid Tumor Oncology. Dr. Kim went to medical school at Northwestern University and completed his residency at Baylor College of Medicine and Fellowship at MD Anderson Cancer Center.

Publications

Molecular Therapy. N…

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation…

Genomic Medicine

Somatic cancer variant curation and harmonization through consensus minimum variant level data…

Cancer

Modulation of c-Met Signaling and Cellular Sensitivity to Radiation…

Molecular Therapy. N…

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation…

Nature Communication…

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression…

Cancer Research

Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy…

Cancer Immunology Re…

Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?…

International Journa…

Lymphopenia Association With Gross Tumor Volume and Lung V5 and It’s Effects on Non-Small Cell Lung Cancer Patient Outcomes…

Keystone Symposia Po…

MolecularMatch Poster “Genotype based therapeutics and clinical trials search engine” from the 2016 Keystone Symposia on Molecular and Cellular Biology…

Keystone Symposia 20…

MolecularMatch Abstract “Genotype based therapeutics and clinical trials search engine” for the 2016 Keystone Symposia on Molecular and Cellular Biology…

Journal of Clinical …

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Therapy for Patients with Brain Metastases From Non-Small-Cell Lung Cancer…

Journal of the Natio…

PDL1 Regulation by p53 via miR-34…

Clinical Cancer Rese…

Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells…

News

MolecularMatch Announces new SDK and Improved Drug Search
MolecularMatch Announces new SDK and Improved Drug Search Houston – October 2, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced the release of MMPower v4, the latest update to its Clinical Decision Support platform. This new release adds expanded therapeutic guidance and …
Read More
MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service
MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service Houston – August 08, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that the United States Patent and Trademark Office has issued US Patent 10,360,349 covering its Precision Medicine Service …
Read More
MolecularMatch appoints Eric Pulaski as President
MolecularMatch appoints Eric Pulaski as President Pulaski joins executive team to drive product strategy and revenue growth Houston – June 24, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that Eric Pulaski will serve as President for MolecularMatch. Pulaski has over …
Read More
Roche Launches First Two NAVIFY Clinical Decision Support Apps
Roche Launches First Two NAVIFY Clinical Decision Support Apps Basel Switzerland – Roche (September 18, 2018) – (RTTNews) – Swiss drug major Roche Group (RHHBY) announced Tuesday the launch of the first two NAVIFY clinical decision support apps: The NAVIFY Clinical Trial Match and NAVIFY Publication Search apps. The two …
Read More
Loading...